Shanghai Mianyi Biopharmaceutical Co., Ltd. | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)	DNA Virus Infections, Disease Attributes, Genital Diseases, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, Urogenital Diseases, human papilloma virus infection, infectious disease, sexually transmitted disease, viral infectious disease, viral sexually transmitted disease	Not yet recruiting	Phase 1 / Phase 2	2026-06-25		NCT07668960
Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder	Recruiting	Phase 2 / Phase 3	2026-03-17		NCT06111638
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.	Duchenne muscular dystrophy	Recruiting	Phase 1 / Phase 2	2025-12-04		NCT07058662
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne muscular dystrophy, Muscular Disorders, Atrophic, X-linked disease, hereditary disease, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, nervous system disorder, neuromuscular disease	Recruiting	Early phase 1	2025-03-25		NCT06641895